SANDIMMUNE Drug Patent Profile
✉ Email this page to a colleague
When do Sandimmune patents expire, and what generic alternatives are available?
Sandimmune is a drug marketed by Novartis and is included in three NDAs.
The generic ingredient in SANDIMMUNE is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sandimmune
A generic version of SANDIMMUNE was approved as cyclosporine by HIKMA on October 29th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SANDIMMUNE?
- What are the global sales for SANDIMMUNE?
- What is Average Wholesale Price for SANDIMMUNE?
Summary for SANDIMMUNE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 89 |
| Clinical Trials: | 99 |
| Patent Applications: | 4,345 |
| Drug Prices: | Drug price information for SANDIMMUNE |
| What excipients (inactive ingredients) are in SANDIMMUNE? | SANDIMMUNE excipients list |
| DailyMed Link: | SANDIMMUNE at DailyMed |
Recent Clinical Trials for SANDIMMUNE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fred Hutchinson Cancer Center | Phase 2 |
| National Cord Blood Network | Phase 2 |
| Berinstein, Jeffrey | Phase 4 |
Pharmacology for SANDIMMUNE
| Drug Class | Calcineurin Inhibitor Immunosuppressant |
| Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
US Patents and Regulatory Information for SANDIMMUNE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-001 | Mar 2, 1990 | AB2 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | SANDIMMUNE | cyclosporine | INJECTABLE;INJECTION | 050573-001 | Nov 14, 1983 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-003 | Nov 23, 1992 | BX | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-002 | Mar 2, 1990 | AB2 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novartis | SANDIMMUNE | cyclosporine | SOLUTION;ORAL | 050574-001 | Nov 14, 1983 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SANDIMMUNE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-001 | Mar 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-002 | Mar 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | SANDIMMUNE | cyclosporine | CAPSULE;ORAL | 050625-003 | Nov 23, 1992 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SANDIMMUNE
See the table below for patents covering SANDIMMUNE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| United Kingdom | 9003616 | ⤷ Sign Up | |
| United Kingdom | 8903804 | ⤷ Sign Up | |
| Switzerland | 680650 | ⤷ Sign Up | |
| Cyprus | 1886 | Novel cyclosporin galenic forms | ⤷ Sign Up |
| Japan | H0611703 | ⤷ Sign Up | |
| Italy | 9047650 | ⤷ Sign Up | |
| Germany | 4005190 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SANDIMMUNE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2049079 | LUC00006 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
